Diagnostics (May 2023)

CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

  • Valerio Nardone,
  • Maria Paola Belfiore,
  • Marco De Chiara,
  • Giuseppina De Marco,
  • Vittorio Patanè,
  • Giovanni Balestrucci,
  • Mauro Buono,
  • Maria Salvarezza,
  • Gaetano Di Guida,
  • Domenico D’Angiolella,
  • Roberta Grassi,
  • Ida D’Onofrio,
  • Giovanni Cimmino,
  • Carminia Maria Della Corte,
  • Antonio Gambardella,
  • Floriana Morgillo,
  • Fortunato Ciardiello,
  • Alfonso Reginelli,
  • Salvatore Cappabianca

DOI
https://doi.org/10.3390/diagnostics13101717
Journal volume & issue
Vol. 13, no. 10
p. 1717

Abstract

Read online

Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.

Keywords